AstraZeneca welcomes positive data on the combination of olaparib and cediranib for the treatment of ovarian cancer patients
As part of the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO), Dr Joyce Liu today presented data on a Phase II study conducted by the American National Cancer Institute (NCI)